SecBot SecBot
8-K ·Filed Oct 26, 2026

CLYM

Climb Bio, Inc.
BULLISH
Impact 6/10
Processed55m ago SEC0001193125-26-430997
8-K context-dependent: Items 7.01, 8.01

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-430997
Document: clym-20261024.htm0001193125-26-430997
Document: clym-ex99_1.htm0001193125-26-430997
Document: 0001193125-26-430997-index-headers.html0001193125-26-430997
Document: 0001193125-26-430997-index.html0001193125-26-430997
Document: 0001193125-26-430997.txt0001193125-26-430997
20 reports for CLYM
Performance horizon
80% Hit rate @ T+1 4 of 5 directional calls Went positive at some point 4 of 5 best @ T+1▲ +6.79%Jun 12, 2026
Filters
Rows
Reports for CLYM — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
BULLISH ★ 6/10
—awaiting T+1——
Oct 23, 2026
2d ago
8-K
BULLISH ★ 7/10
$10.47awaiting T+1—$10.19 (−2.67%)
Oct 23, 2026
2d ago
Press Release
BULLISH ★ 7/10
$10.34awaiting T+1—$10.19 (−1.45%)
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$14.21 $12.52▼ −11.89%▼ −11.17%$10.19 (−28.29%)
Sep 3, 2026
7w ago
8-K
BULLISH ★ 7/10
$14.59 $15.52▲ +6.37%▲ +6.76%$10.19 (−30.16%)
Aug 14, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$16.33 $17.44▲ +6.80%▲ +7.27%$10.19 (−37.60%)
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$14.00 $14.00· 0.00%▼ −0.61%$10.19 (−27.21%)
Jun 30, 2026
16w ago
144
NEUTRAL ★ 3/10
$13.29 $12.90▼ −2.93%▼ −2.80%$10.19 (−23.33%)
Jun 12, 2026
19w ago
8-K
BEARISH ★ 5/10
$11.49 $10.71▲ +6.79%▲ +6.19%$10.19 (+11.31%)
Jun 12, 2026
19w ago
424B5
BEARISH ★ 6/10
$11.49 $10.71▲ +6.79%▲ +6.19%$10.19 (+11.31%)
Showing 10 of 20

US Market Status

Market Closed — Opens in 2h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh CLYM Intelligence

Analysis is for subscribers only.

Climb Bio announced initial Phase 2 data from its PrisMN trial of budoprutug in primary membranous nephropathy (pMN) at ASN Kidney Week 2026. The 200 mg cohort showed a mean 70% reduction in anti-PLA2R antibodies at Week 12, with 38% of patients achieving immunologic remission.

Subscribe for Full Access